Edwards Lifesciences Files 8-K on Financials
Ticker: EW · Form: 8-K · Filed: Oct 30, 2025 · CIK: 1099800
| Field | Detail |
|---|---|
| Company | Edwards Lifesciences Corp (EW) |
| Form Type | 8-K |
| Filed Date | Oct 30, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: EW
TL;DR
EDWARDS LIFESCIENCES (EW) FILED AN 8-K ON 10/30/25 DETAILING FINANCIALS.
AI Summary
Edwards Lifesciences Corporation filed an 8-K on October 30, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits. The filing details the company's financial performance and provides supporting documentation.
Why It Matters
This filing provides investors with crucial updates on Edwards Lifesciences' financial health and operational results, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate negative or positive news indicated.
Key Players & Entities
- Edwards Lifesciences Corp (company) — Registrant
- October 30, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Irvine, California (location) — Principal Executive Offices
FAQ
What specific financial information is being reported in this 8-K?
The 8-K reports on the 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on October 30, 2025.
What is the principal executive office address for Edwards Lifesciences Corporation?
The principal executive offices are located at One Edwards Way, Irvine, California 92614.
What is the SEC file number for Edwards Lifesciences Corporation?
The SEC file number is 001-15525.
What is the SIC code for Edwards Lifesciences Corporation?
The Standard Industrial Classification (SIC) code is 3842 for Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Filing Stats: 500 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-10-30 16:18:04
Key Financial Figures
- $1.00 — ich registered Common Stock, par value $1.00 per share EW New York Stock Exchange
Filing Documents
- ew-20251030.htm (8-K) — 33KB
- ex-991q32025.htm (EX-99.1) — 517KB
- ew45percentblacklrga21.jpg (GRAPHIC) — 625KB
- 0001099800-25-000059.txt ( ) — 1552KB
- ew-20251030.xsd (EX-101.SCH) — 2KB
- ew-20251030_lab.xml (EX-101.LAB) — 21KB
- ew-20251030_pre.xml (EX-101.PRE) — 12KB
- ew-20251030_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 30, 2025, Edwards Lifesciences Corporation, a Delaware corporation ("Edwards"), issued a press release setting forth Edwards' financial results for the third quarter of 2025. A copy of the press release is furnished as Exhibit 99.1, and is incorporated herein by reference. The information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of the Securities Exchange Act of 1934, as amended.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 99.1 Press release, dated October 30, 2025, reporting Edwards' financial results for the third quarter of 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2025 EDWARDS LIFESCIENCES CORPORATION By: /s/ Scott B. Ullem Scott B. Ullem Chief Financial Officer 3 Exhibit Index Exhibit Number Description 99.1 Press release, dated October 30, 2025, reporting Edwards' financial results for the third quarter of 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 4